All News

podcastLogo-01%20RESIZED.jpg

Rheumnow Podcast - ACR 2020 Retrospective (11.13.20)

Jack Cush, MD

Dr. Jack Cush reviews this past week at Virtual ACR 2020 - highlights from the meeting and his view of best/newest studies.

What will people remember or talk about from ACR 2020?

Read Article
ACR20 Podcast

ACR20 - Day 5.1 & 5.2 Podcasts

Jack Cush, MD

Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.



Listen here:

Read Article
ACR Mon

ACR20 - Day 4 Report

Jack Cush, MD

Here are my highlights from day four, Monday, of the ACR 2020 Convergence. 



Vaccine Immunogenicity with Tofacitinib

Read Article
ACR20 Podcast

ACR20 - Day 5 Podcast

Jack Cush, MD

Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.



Listen here:

Read Article
ACR20 Podcast

ACR20 - Day 4.6 & 4.7 Podcasts

Jack Cush, MD

Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.



Listen here:

Read Article
ACR20 Podcast

ACR20 = Day 4.4 & 4.5 Podcasts

Jack Cush, MD

Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.



Listen here:

Read Article
Roundup RHeum ACR

Rheumatology Round-Up with Drs. Kavanaugh & Cush

Jack Cush, MD

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!


Read Article
Best of

ACR Best Abstracts - Day 4

Jack Cush, MD

The final day (day 4) of the ACR 2020 meeting saw a flurry of late-breaking abstracts and other novel studies that excited our faculty. Below are some of their choices for #ACRbest.

Read Article
meeting.audience.3.jpg

Rheumatology Round-Up 2020 Tonight!

Jack Cush, MD

Rheumatology Round-Up tonight 8:00pm EST, 7pm CST.  Drs. Artie Kavanaugh and Jack Cush reprise their long-running end of ACR highlights. Rheums can watch by Zoom (Q&A too), everyone can watch on RheumNow.com or our YouTube channel. See you there!

Read Article
Inadequate response to MTX, what next? “Are you forward thinking or are you stuck in the past? Conceptually it is just amazing that you can take a PO tablet as potent as a TNF or IL6 blocker... & the side effects are not so appalling.”—Dr. GreggSilverman. @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

When do you think we are going to get a DMARD for OA? 50% or more over age 60 will have osteoarthritis, yet we are yet to discover a promising disease modifying therapy. #ACR20 @RheumNow @ElaineHusniMD

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Summary of #ACR20 part A: - HCQ is not a problem in rheumatic dz pts in terms of causing QTc prolongation - Anti-phospholipid ab are found in a majority of hospitalized COVID19 pts — the most prevalent of which were anti-PST abs that are not in the of criteria for APS @rheumnow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w): 2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20 @Rheumnow

Eric Dein ejdein1 ( View Tweet)

Abst#2000. PRIME team Medicare database study pts with new RA started on MTX higher VTE risk than HCQ (HR 2.3). Unable to assess disease activity because claims database, but would imagine MTX grp more severe, driving increased VTE risk @RheumNow #ACR20 https://t.co/Z14xFTVXTp
Eric Dein ejdein1 ( View Tweet)
COX2 inhibitors associated with inhibition of radiographic spinal progression in AxSpA pts compared to non-selective NSAIDs. ⬇️radiographic spinal progression over 2 yrs ⬇️mSASSS progression @RheumNow #ACR20 Abs#2030 https://t.co/p1CeNBm3ma
Robert B Chao, MD doctorRBC ( View Tweet)
Late breaking: in older #rheumatoidarthritis patients, those taking MTX have 2x risk of #VTE compared to those on HCQ. Important to consider #thromboembolic risk factors when starting new RA treatment. Abs#2000 #ACR20 @RheumNow https://t.co/lt8xDT4Ne8

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

Which DMARD would you use in an RA pt Rx naive pt with mod dz activity and who has RA lung dz? #acr20 @RheumNow

k dao KDAO2011 ( View Tweet)

Large cohort of older RA pts newly rx w/HCQ or MTX: 👉~2-fold ⬆ risk of VTE – both PE and DVT- among patients newly treated with MTX vs. HCQ. @RheumNow #ACR20 abs#2000 @DanielHSolomon https://t.co/ZnDuMhTMYF
sheila RHEUMarampa ( View Tweet)
HCQ not associated with ⬆ incidence of cardiac dse in this cohort of RA pts. We should continue using it. Benefits >>>risks. @RheumNow #ACR20 abs1999 https://t.co/zYpbX0CsR1
sheila RHEUMarampa ( View Tweet)
NEW ACR2020 Draft Guidelines for the Pharmacologic Treatment of RA All the guidelines in 2 tables! 1. MTX 1st, oral > SC 2. Minimize GC! 3. TTT TTT TTT 4. Biologic/tsDMARD > Triple Tx 5. Taper MTX 1st Close to my practice; suspect will be controversial! #ACR20 #ACRambassador https://t.co/iFSlq1H65V
Mike Putman EBRheum ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×